将来这一诊疗模式还有很大的完善空间。比如家庭医生和社区医生与居民联系紧密，对孩子的健康 状况有较为全面的了解，他们可以根据孩子的既往病史、过敏史等信息，为家长提供专业的建议，协助 家长选择更合适的检查项目，从而显著提升开单检查的准确性与安全性。社区医生还能在后续的诊疗过 程中，根据检查结果和孩子的病情变化，及时给予指导和干预，实现从诊前检查到诊断治疗的一站式服 务，进一步优化诊疗流程。 诊前检查线上开单不仅适用于儿科，其他科室其实也可以借鉴。在医院的很多科室都存在着患者等 待时间长、就诊流程繁琐等问题。比如，内科的很多疾病在诊断前也需要进行一系列的检查，如血常 规、尿常规、心电图等。如果这些疾病也能推行诊前检查线上开单，不仅能减少患者在医院的等待时 间，还能让医生有更多的时间与患者沟通。很多慢性病患者"久病成良医"，对自己何时复查和怎么复查 了如指掌，在确保安全的前提下，可以列出诊前检查项目清单，供他们自行或在家庭医生的指导下进行 选择。 将诊前检查从应急举措升级为创新智慧，不仅利于化解当前的难题，而且还能推动整个医疗模式的 变革与发展。期待诊前检查线上开单这一创新智慧能够在更多领域得到尝试和应用，让看病难经 ...

证券之星消息，国际医学(000516)12月01日在投资者关系平台上答复投资者关心的问题。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 投资者提问：请问贵公司是否为家族企业或者裙带企业？ 国际医学回复：您好，感谢您对公司的关注。国际医学作为一个已上市的公众公司，自创立以来，始终 致力于建立并不断完善现代化的企业治理结构，以确保公司的专业化、规范化和可持续发展。公司严格 遵循《公司法》《证券法》及上市公司治理准则等法律法规，建立了以股东会、董事会和经营管理层为 核心的治理架构，有效保障所有股东的合法权益，确保公司重大决策的科学性与透明度。公司采用"集 团化管理，分院区经营"的模式，旗下医疗机构建立了完善的现代化企业制度和专业的医疗技术、人力 资源、财务管理、专业培训等管理体系。公司具备健全且运行良好的法人治理结构，建立了健全的内部 控制制度，能够有效保证公司运行的效率、提高公司的经营能力。谢谢！ ...

Core Viewpoint - The company is addressing investor concerns regarding declining revenue and profits while maintaining operational efficiency through cost management strategies [1] Financial Performance - As of Q3 2025, the company's management expense ratio is 10.99%, showing a year-on-year decrease of 0.54 percentage points and a quarter-on-quarter decrease of 2.13 percentage points [1] - The financial expense ratio stands at 3.43%, with a year-on-year decrease of 0.07 percentage points and a quarter-on-quarter decrease of 0.25 percentage points [1] Cost Management Strategies - The company is focusing on optimizing medical service quality, clinical pathway management, reducing drug consumption, and optimizing cost structure to enhance operational efficiency [1] - Future efforts will continue to emphasize cost control, with expectations for further optimization of financial costs as depreciation and interest expenses decline [1]

（原标题：专访英中贸易协会主席：中英经济高度互补，大湾区成合作新高地） 英中贸易协会是英国促进对华贸易和投资的国家级商业贸易网络。协会成立于1954年，与中国的联系超 过70多年。目前，英中贸易协会服务近千家会员公司，在英国和中国的大部分地区拥有专业服务团队。 英中贸易协会的现有会员企业中，约15%是中资企业。展望未来，吴思田表示，英中贸易协会将继续服 务会员企业拓展业务和增加盈利，"我的目标就是让所有会员企业取得更大的商业成功，就是如此简 单。" 建设健康稳固的经贸关系 《21世纪》：你拥有丰富的外交与商业经验，曾担任英国驻华大使，现为施罗德投资集团中国事务主 席。这些经历如何塑造了你在推动中英双边贸易与投资方面的愿景？ 南方财经 21世纪经济报道记者 袁思杰 深圳报道 "在今后中国的发展进程中，中英两国的经济结构正展现出高度的互补特征。"英中贸易协会新任主席、 前英国驻华大使吴思田(Sebastian Wood)对记者表示。 11月20日，由英中贸易协会主办的2025英国-粤港澳大湾区大会在深圳前海举行。论坛间隙，吴思田接 受了21世纪经济报道记者的专访，就中英经贸关系、中国市场和粤港澳大湾区发展机遇等话 ...

Core Insights - The 2025 "Honorary Doctors" and "National Famous Doctors" awards highlight the achievements of Chinese medical professionals in overcoming difficult medical challenges and advancing medical technology and research [1][2][3] Group 1: Medical Innovation - Medical innovation is rooted in clinical practice, emerging from every patient consultation and surgical breakthrough [2][3] - The focus of medical innovation is to address patient pain and improve their quality of life, rather than merely pursuing advanced technology for its own sake [2][3] Group 2: Clinical Practice and Patient Care - Clinical innovation is driven by the need to enhance surgical precision, reduce recovery time, and optimize patient experience [3][5] - Successful case studies, such as the development of a minimally invasive eye surgery technique, demonstrate the impact of clinical innovation on patient outcomes [3][5] Group 3: Future Directions in Healthcare - The integration of artificial intelligence in medicine is reshaping healthcare delivery, extending the role of doctors beyond hospitals to community and home settings [6] - Key future pillars of medical development include precision prevention, innovative drugs, minimally invasive interventions, and organ transplantation [6]

Core Viewpoint - Southbound funds have significantly increased their holdings in Jinxin Reproductive Medicine (01951.HK), indicating strong investor interest in the company [1] Group 1: Shareholding Changes - On December 1, southbound funds increased their holdings by 2.9025 million shares, representing a 0.20% change [2] - Over the past five trading days, there has been a cumulative net increase of 27.119 million shares held by southbound funds [1][2] - In the last 20 trading days, southbound funds have increased their holdings on 15 occasions, with a total net increase of 48.7178 million shares [1] Group 2: Current Holdings - As of now, southbound funds hold a total of 1.485 billion shares of Jinxin Reproductive Medicine, accounting for 53.83% of the company's issued ordinary shares [1][2] Group 3: Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment, mainly in China and the United States [2]

Core Viewpoint - The announcement highlights the confidence of the company's non-executive director, Ms. Li Fangyu, in the future development of the company through her acquisition of 41,500 shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] Group 1: Share Acquisition - Ms. Li Fangyu increased her stake in the company by acquiring 41,500 ordinary shares through LIFY Management Holdings Limited in the open market [1] - The company repurchased 80,000 shares on December 1, 2025, for a total consideration of approximately HKD 2.0008 million, with an average transaction price of about HKD 25.01 per share [1] - From October 15, 2025, to the announcement date, the company has repurchased a total of 775,000 shares at a total cost of approximately HKD 22.6932 million [1] Group 2: Management Confidence - The board of directors believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The board expresses confidence that the share repurchase demonstrates management's strong belief in the long-term value of the enterprise, which is beneficial for enhancing the company's market value and shareholder return capabilities [1] - The share repurchase aligns with the overall interests of the company and its shareholders [1]

Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), has announced a share buyback program, indicating that its current trading price does not reflect its intrinsic value or actual business prospects [1] Group 1: Share Buyback Announcement - The company is authorized to repurchase up to 274 million shares, which represents 10% of the total shares issued as of the date of the annual general meeting, excluding treasury shares [1] - The board of directors has resolved to utilize the buyback authorization to repurchase shares in the open market at a total price of no less than HKD 100 million [1] - The proposed share buyback is seen as a demonstration of the company's confidence in its business development prospects [1] Group 2: Financial Position - The company believes that its existing financial resources are sufficient to support the proposed share buyback while maintaining a robust financial position [1]

Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), has announced a share buyback plan, indicating that its current trading price does not reflect its intrinsic value or actual business prospects [1] Group 1: Share Buyback Details - The company is authorized to repurchase up to 274 million shares, which represents 10% of the total shares issued as of the date of the annual general meeting, excluding treasury shares [1] - The board has resolved to utilize the buyback authorization to repurchase shares in the open market for a total price of no less than HKD 100 million [1] Group 2: Rationale and Financial Position - The company believes that the proposed share buyback will demonstrate its confidence in its business development prospects [1] - The existing financial resources of the company are deemed sufficient to support the implementation of the proposed share buyback while maintaining a robust financial position [1]

Core Viewpoint - Zhongji Changshou Science (00767) plans to acquire 25% of the issued share capital of Comprehensive Cell Bank Limited from China International Orthopedic Medical Group Co., Ltd. for an initial consideration of HKD 300 million, with the possibility of issuing redeemable convertible bonds up to HKD 300 million to finance this acquisition [1] Group 1: Acquisition Details - The acquisition is set to take place on December 1, 2025, with an initial payment of HKD 300 million [1] - The company will issue redeemable convertible bonds to cover the initial consideration, with a maximum amount of HKD 300 million [1] Group 2: Target Company Operations - The target company operates a boutique high-end customized stem cell and IPSC storage center, providing testing and preclinical immunotherapy services to clients, particularly high-net-worth individuals in Hong Kong and mainland China [1] - The target company operates under the trade names of Weisman Academician International Advanced Medical Center and Asia International Medical Testing Center, staffed by registered doctors and laboratory technicians [1] Group 3: Market Potential - The board believes that stem cell and IPSC storage services, along with cellular immunotherapy medical services, represent a new business area with significant growth potential [1] - Cellular immunotherapy services are experiencing exponential growth, driven by increased consumer demand and investment interest in advanced skin regeneration, comprehensive vitality enhancement, holistic health management, and proactive health management strategies [1]